262 related articles for article (PubMed ID: 29849166)
41. Which factors impact on quality of life for adults with blepharospasm and hemifacial spasm?
Lawes-Wickwar S; McBain H; Hirani SP; Hurt CS; Dunlop N; Solly D; Crampton B; Newman SP; Ezra DG
Orbit; 2021 Apr; 40(2):110-119. PubMed ID: 32116098
[No Abstract] [Full Text] [Related]
42. [The effect of botulinum A toxin repeated injection in treating blepharospasm and hemifacial spasm].
Wang J; Zhang X
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr; 20(7):292-4. PubMed ID: 16780139
[TBL] [Abstract][Full Text] [Related]
43. Influence of involuntary eyelid spasms on corneal topographic and eyelid morphometric changes in patients with hemifacial spasm.
Osaki T; Osaki MH; Osaki TH; Hirai FE; Nallasamy N; Campos M
Br J Ophthalmol; 2016 Jul; 100(7):963-970. PubMed ID: 26541432
[TBL] [Abstract][Full Text] [Related]
44. Botulinum toxin treatment of hemifacial spasm and blepharospasm: objective response evaluation.
Thussu A; Barman CR; Prabhakar S
Neurol India; 1999 Sep; 47(3):206-9. PubMed ID: 10514580
[TBL] [Abstract][Full Text] [Related]
45. Positive effect of self-exercise following Botulinum toxin injection on the permanence of the recovery among the patients with HFS and BFS: A clinical trial.
Sari ÜS; Eroglu M; Büyükşerbetçi G; Tokucoglu F; Sahin N
Medicine (Baltimore); 2024 Jun; 103(24):e38215. PubMed ID: 38875371
[TBL] [Abstract][Full Text] [Related]
46. Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.
Czyz CN; Burns JA; Bergstrom RE
J Neuroophthalmol; 2021 Dec; 41(4):e684-e687. PubMed ID: 33470741
[TBL] [Abstract][Full Text] [Related]
47. Five-Year Retrospective Review of Cases with Benign Essential Blepharospasm and Hemifacial Spasm Presenting in a Tertiary Eye Care Center in North India.
Raj A; Arya SK; Deswal J; Bamotra RK
Semin Ophthalmol; 2017; 32(3):371-376. PubMed ID: 27078720
[TBL] [Abstract][Full Text] [Related]
48. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
[TBL] [Abstract][Full Text] [Related]
49. [Botulinum toxin therapy for focal dystonia].
Hahn K; Niklai E; Garzuly F; Szupera Z
Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
[TBL] [Abstract][Full Text] [Related]
50. [Therapeutic use of botulinum toxin in otorhinolaryngology. 1: Treatment of movement disorders of mimetic muscles].
Laskawi R
HNO; 1998 Mar; 46(3):281-7. PubMed ID: 9583037
[No Abstract] [Full Text] [Related]
51. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
[TBL] [Abstract][Full Text] [Related]
52. Use of botulinum toxin A in the treatment of hemifacial spasm and blepharospasm.
Chang LB; Tsai CP; Liao KK; Kao KP; Yuan CL; Yen DJ; Lin KP
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jan; 62(1):1-5. PubMed ID: 10063705
[TBL] [Abstract][Full Text] [Related]
53. Complications of Preseptal Versus Pretarsal Botulinum Toxin Injection in Benign Essential Blepharospasm: A Randomized Controlled Trial.
Sanguandikul L; Apinyawasisuk S; Jariyakosol S; Hirunwiwatkul P; Chongpison Y
Am J Ophthalmol; 2021 Dec; 232():9-16. PubMed ID: 33965414
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm.
Li XH; Lin SC; Hu YF; Liu LY; Liu JB; Hong YC
Eye Sci; 2012 Dec; 27(4):178-81. PubMed ID: 23225838
[TBL] [Abstract][Full Text] [Related]
55. Low-dose botulinum toxin a for treatment of blepharospasm and hemifacial spasm.
Poonyathalang A; Preechawat P; Jamnansiri U
Jpn J Ophthalmol; 2005; 49(4):327-8. PubMed ID: 16075337
[No Abstract] [Full Text] [Related]
56. [Costs and efficacy of type A botulinum toxin for the treatment of essential blepharospasm and hemifacial spasm].
Lasalvia CG; Pereira Lde S; da Cunha MC; Kitadai SP
Arq Bras Oftalmol; 2006; 69(5):701-5. PubMed ID: 17187139
[TBL] [Abstract][Full Text] [Related]
57. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
Hosotani Y; Yokoi N; Okamoto M; Ishikawa H; Komuro A; Kato H; Mimura O; Gomi F
Jpn J Ophthalmol; 2020 Jan; 64(1):45-53. PubMed ID: 31823132
[TBL] [Abstract][Full Text] [Related]
58. Botulinum toxin type a injection for lateral canthal rhytids : effect on tear film stability and tear production.
Ho MC; Hsu WC; Hsieh YT
JAMA Ophthalmol; 2014 Mar; 132(3):332-7. PubMed ID: 24385079
[TBL] [Abstract][Full Text] [Related]
59. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
Badarny S; Susel Z; Honigman S
Isr Med Assoc J; 2008 Jul; 10(7):520-2. PubMed ID: 18751631
[TBL] [Abstract][Full Text] [Related]
60. A comparison of facial muscle squeezing versus non-facial muscle squeezing on the efficacy of botulinumtoxin-A injections for the treatment of facial dystonia.
O' Reilly P; Ross J; Norris J; Malhotra R
Orbit; 2012 Dec; 31(6):400-3. PubMed ID: 23061606
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
